(AIM: SAR)                                                                                                                                          8 November 2018



("Sareum" or "the Company")

Sareum notes Sierra Oncology has reported Third Quarter 2018 Results


Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, has reported its Third Quarter 2018 Results including reference to the ongoing development of SRA737.

In the statement, Sierra CEO Nick Glover commented that Sierra has made substantial progress enrolling genetically-selected patients into the indication-specific cohorts of two SRA737 trials, with a focus on recruiting patients with High Grade Serous Ovarian Cancer (HGSOC). Preliminary efficacy results from these trials are expected to be reported in the first half of 2019.

Sierra has also continued preparing for the initiation of a Phase 1b/2 trial of SRA737 with the PARP inhibitor niraparib, which will evaluate this combination in subjects with metastatic castration-resistant prostate cancer (mCRPC).

Title of announcement: Sierra Oncology Reports Third Quarter 2018 Results

Link to announcement: https://www.prnewswire.com/news-releases/sierra-oncology-reports-third-quarter-results-300744943.html

For further information, please contact: 

Sareum Holdings plc


Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser)

Chris Fielding / James Sinclair-Ford

020 7220 1666

Hybridan LLP (Broker)


Claire Noyce

020 3764 2341

Citigate Dewe Rogerson (Media enquiries)


 Shabnam Bashir/ Mark Swallow/ David Dible

 020 7638 9571

Notes for editors: 

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics, to improve the treatment of cancer and autoimmune disease. The Company generates value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum’s leading clinical-stage programme, SRA737, a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology, is in Phase 2 clinical trials targeting ovarian and other advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in combination with other oncology and immune-oncology drugs in genetically defined patients.

Sareum is also advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) /Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases and cancers. TYK2 and JAK1 have roles in pro-inflammatory responses in autoimmune diseases (e.g. psoriasis, rheumatoid arthritis, inflammatory bowel diseases and lupus) and tumour cell proliferation in certain cancers (e.g. T-cell acute lymphoblastic leukaemia and some solid tumours). The Company is targeting first human clinical trials in each indication in 2020.

The Company also has an Aurora+FLT3 inhibitor targeting haematological cancers, which is at the preclinical development stage.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk

- Ends -